Literature DB >> 6492074

2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.

E von Angerer, J Prekajac, J Strohmeier.   

Abstract

A number of 2-phenylindole derivatives with one hydroxy group in the meta or para position of the phenyl ring and a second one in position 5, 6, or 7 of the indole nucleus were synthesized. In addition, different alkyl groups were introduced into positions 1 and 3 of the heterocycle. The influence of these structural variations on the binding affinity for the calf uterine estrogen receptor was studied. A prerequisite for the binding is the presence of an alkyl group at the nitrogen. Favorable are a hydroxy group located in the para position of the phenyl ring and short alkyl chains both in position 1 and 3 of the indole. The highest relative binding affinity (RBA) values (e.g., 33 for 20b, 21 for 24b, 23 for 35b) are close to that of hexestrol (RBA = 25, estradiol = 100). Depending on the positions of the oxygen functions and size of the alkyl residues, the indole derivatives behaved as strong estrogens (20c, 24c, 35c) or impeded estrogens with antagonistic activity (23c, 29c, 30c, 31c, 40c, 44c) in the immature mouse. Some of these derivatives (20c, 23c, 24c, 29c, 30c, 31c) were tested for their inhibitory effect on dimethylbenzanthracene-induced hormone-dependent mammary tumors of the rat. Both types exhibited a strong growth inhibition with a reduction of the average tumor area at appropriate dosage. A mode of action involving the estrogen receptor system is assumed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6492074     DOI: 10.1021/jm00377a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.

Authors:  Mallinath B Hadimani; Matthew T Macdonough; Anjan Ghatak; Tracy E Strecker; Ramona Lopez; Madhavi Sriram; Benson L Nguyen; John J Hall; Raymond J Kessler; Anupama R Shirali; Li Liu; Charles M Garner; George R Pettit; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Nat Prod       Date:  2013-09-09       Impact factor: 4.050

2.  The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat.

Authors:  E von Angerer; H Birnböck; M Kager; A Maucher
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.

Authors:  S M Rink; K J Yarema; M S Solomon; L A Paige; B M Tadayoni-Rebek; J M Essigmann; R G Croy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  Antitumour activity of coumarin and 7-hydroxycoumarin against 7,12-dimethylbenz[a]anthracene-induced rat mammary carcinomas.

Authors:  A Maucher; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Tethered indoles as functionalizable ligands for the estrogen receptor.

Authors:  Bridget G Trogden; Sung Hoon Kim; Shuyi Lee; John A Katzenellenbogen
Journal:  Bioorg Med Chem Lett       Date:  2008-11-18       Impact factor: 2.823

Review 6.  Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.

Authors:  Luigi Gennari; Daniela Merlotti; Fabrizio Valleggi; Giuseppe Martini; Ranuccio Nuti
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  The inhibitory effect of 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-6-hydroxyindole (D 15413) on estrogen-dependent mammary tumors.

Authors:  E von Angerer; J Prekajac; M R Schneider; M R Berger
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

Review 8.  Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?

Authors:  Stephen R D Johnston
Journal:  Breast Cancer Res       Date:  2005-04-06       Impact factor: 6.466

9.  Quantitative structure-activity relationships (QSARs) for estrogen binding to the estrogen receptor: predictions across species.

Authors:  W Tong; R Perkins; R Strelitz; E R Collantes; S Keenan; W J Welsh; W S Branham; D M Sheehan
Journal:  Environ Health Perspect       Date:  1997-10       Impact factor: 9.031

10.  Synthesis and molecular docking of novel non-competitive antagonists of GluK2 receptor.

Authors:  Agnieszka A Kaczor; Tomasz Wróbel; Christiane Kronbach; Klaus Unverferth; Tomasz Stachal; Dariusz Matosiuk
Journal:  Med Chem Res       Date:  2014-07-24       Impact factor: 1.965

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.